NEW YORK (GenomeWeb) – Melanoma test development firm DermTech International has filed to go public with a proposed offering of up to $25 million in stock.

The company filed its preliminary prospectus with the US Securities and Exchange Commission on Friday. It has not yet priced its shares or said how many shares it plans to offer.

DermTech plans to list its shares on the Nasdaq Capital Market under ticker symbol "DMTK." The underwriters on the offering are the Maxim Group and Feltl & Co.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.